Portfolio company
CDR-Life
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
3 investors
Sectors
About
The company develops antibody-based T cell engagers to treat patients with solid tumours and autoimmune diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
T-Therapeutics
The company develops T cell receptor therapeutics and bispecific engagers for patients with cancer and autoimmune diseases.
Candid Therapeutics
This clinical-stage biotechnology company develops T-cell engager antibodies for patients with autoimmune and inflammatory diseases.
Anaveon
The company develops precision biologics and engineered antibodies to treat patients with cancer and autoimmune diseases.
Captain T Cell
The company develops cell therapies for cancer patients to treat solid tumours.
Clasp Therapeutics
This company develops T cell engagers that target oncogenic driver mutations to treat patients with solid tumours.
Cytospire Therapeutics
This company develops multispecific immune cell engager antibodies for cancer patients to enhance and direct immune system activity against solid tumours.
T-CURX
This biotech company develops non-viral CAR-T cell therapies to treat patients with leukaemia, lymphoma and solid tumours.
CellmAbs
This biotech company develops monoclonal antibodies and adoptive cell therapies to treat oncology patients with solid tumours.